Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial

Gastroenterology
R OrenT Gilat

Abstract

Uncontrolled studies have suggested that methotrexate may be effective in patients with active ulcerative colitis. The aim of this study was to evaluate the effectiveness of oral methotrexate in chronic steroid-dependent ulcerative colitis in a randomized, double-blind multicenter trial. Patients with active ulcerative colitis who have received steroids and/or immunosuppressives for at least 4 months during the preceding 12 months with a current Mayo Clinic score of > or = 7 were included in the study. Methotrexate (12.5 mg) or placebo was added to their treatment once weekly for 9 months. Sixty-seven patients were included (methotrexate, 30 patients, placebo, 37 patients). The proportion of patients entering first remission (methotrexate, 46.7%; placebo, 48.6%), the time to reach first remission (methotrexate, 4.1 +/- 1.9 months; placebo, 3.4 +/- 1.7 months), as well as the proportions of patients having a relapse after first remission (methotrexate, 64.3%; placebo, 44.4%) were not significantly different between the two groups. The mean Mayo Clinic score, the mean monthly steroid dose, and the proportion of abnormal laboratory results during the study were also similar. Methotrexate at a weekly oral dose of 12.5 mg was not fo...Continue Reading

Citations

Feb 27, 2010·Inflammatory Bowel Diseases·Hans H HerfarthBruce E Sands
Feb 1, 2004·Clinics in Colon and Rectal Surgery·Uma Mahadevan
Aug 9, 2002·The New England Journal of Medicine·Daniel K Podolsky
May 10, 2011·Drug Design, Development and Therapy·John K TriantafillidisFilippos Georgopoulos
Jan 18, 2008·World Journal of Gastroenterology : WJG·Patricia L Kozuch, Stephen B Hanauer
May 7, 2009·World Journal of Gastroenterology : WJG·Mitsuro ChibaEriko Ushiyama
May 9, 2012·World Journal of Gastroenterology : WJG·Alberto BiondiAlessandro Fichera
May 18, 2011·World Journal of Gastrointestinal Pharmacology and Therapeutics·Ioannis E Koutroubakis
Jun 6, 2014·Expert Opinion on Pharmacotherapy·Cristina BezzioSandro Ardizzone
Mar 22, 2014·Expert Review of Gastroenterology & Hepatology·Anthony O'Connor, Alan C Moss
Aug 8, 2014·Expert Review of Gastroenterology & Hepatology·Ole Haagen NielsenGerhard Rogler
Dec 17, 2008·Expert Review of Gastroenterology & Hepatology·Andrew B Grossman, Robert N Baldassano
May 4, 2013·Expert Review of Gastroenterology & Hepatology·Makoto NaganumaToshifumi Hibi
Feb 2, 2013·Expert Opinion on Emerging Drugs·Selwyn Odes
Dec 1, 2001·Expert Opinion on Biological Therapy·M H HoltmannM F Neurath
Apr 10, 2010·Expert Opinion on Drug Safety·Laura Noddin Rosenberg, Mark A Peppercorn
Nov 21, 2012·Expert Opinion on Emerging Drugs·Sandro ArdizzoneRoberto de Franchis
Dec 19, 2003·Expert Opinion on Pharmacotherapy·Alan Ronald BremnerRobert Mark Beattie
Jul 5, 2005·Expert Opinion on Investigational Drugs·B C McKaig, W A Stack
Dec 4, 2015·Gastroenterology·Franck CarbonnelUNKNOWN Groupe d'Étude Thérapeutique des Affections Inflammatoires Digestives
Oct 13, 2015·Inflammatory Bowel Diseases·Hans H HerfarthKim L Isaacs
Sep 10, 2015·International Journal of Colorectal Disease·Jungmin Lee, Kofi Clarke
Jun 15, 2007·The Surgical Clinics of North America·Cyrus P Tamboli
May 15, 2007·Lancet·Daniel C Baumgart, William J Sandborn
Apr 8, 2010·Journal of Gastroenterology and Hepatology·Choon Jin OoiUNKNOWN Asia Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease
Feb 16, 2005·Alimentary Pharmacology & Therapeutics·F N Aberra, G R Lichtenstein
Feb 16, 2005·Alimentary Pharmacology & Therapeutics·J R F CummingsD P Jewell
Jun 21, 2005·Alimentary Pharmacology & Therapeutics·C A Siegel, B E Sands
Sep 5, 2007·Alimentary Pharmacology & Therapeutics·G Bianchi PorroS Ardizzone
Jan 19, 2007·Alimentary Pharmacology & Therapeutics·T J Creed, C S J Probert
Dec 9, 2010·Alimentary Pharmacology & Therapeutics·S C NgJ J Y Sung
May 31, 2013·Alimentary Pharmacology & Therapeutics·S J MehtaJ O Lindsay
Feb 18, 2011·Alimentary Pharmacology & Therapeutics·L Peyrin-Biroulet, M Lémann
Nov 3, 2009·Journal of Cellular and Molecular Medicine·Gheorghe HundorfeanCassian Sitaru
Mar 13, 2010·Alimentary Pharmacology & Therapeutics·G BouguenL Peyrin-Biroulet
Mar 10, 2015·Gastroenterology·Brian BresslerUNKNOWN Toronto Ulcerative Colitis Consensus Group
Mar 1, 1997·Baillière's Clinical Gastroenterology·W R Connell, A C Taylor

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.